Biolevate, a software leveraging AI- to accelerate clinical trial compliance and regulatory processes, raised €6 million in Seed funding.
EQT Ventures led the investment round with participation from bpifrance and angel investors.
With fresh funds, Biolevate plans to further scale up capabilities of its AI-driven medical writing assistant platform.
Biolevate is a Paris-based software company offering an AI-driven platform, ELISE, designed to support medical writers by optimizing the creation and management of research and compliance documents.
ELISE leverages technologies such as Natural Language Processing (NLP), Computer Vision, and Graph Neural Networks (GNN) to provide real-time collaborative writing that meets rigorous regulatory standards. It offers instant suggestions and edits to text, compliance assistance, and literature review support, effectively serving as an assistant to professionals involved in medical documentation.
In the official press announcement, Joël Belafa, Co-founder and CEO of Biolevate said: “Artificial intelligence has immense potential, and we established Biolevate with a clear mission of using AI to accelerate the development of new therapies, ensuring patients receive life-saving treatments faster.“
“With our platform, medical writing can be accomplished at a much faster rate while ensuring the accuracy of information at every stage of drug discovery and development – ultimately elevating the standard of healthcare,” added Joël Belafa.